


**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

BAYER HEALTHCARE AG, ALCON, INC.,)	
and ALCON MANUFACTURING, LTD.,)	
)	
Plaintiffs,)	
)	
v.)	Civil Action No. 06-234 (SLR)
)	
TEVA PHARMACEUTICALS USA, INC.,)	
)	
Defendant.)	
_____)	

JOINT CLAIM CONSTRUCTION STATEMENT

Pursuant to paragraph 6 of the Scheduling Order in this case, dated July 12, 2006, Plaintiffs and Defendant submit the following list of disputed claim terms or phrases appearing in the asserted claims of U.S. Patent Nos. 4,990,517 ("the '517 patent"), 5,607,942 ("the '942 patent"), and 6,716,830 ("the '830 patent").



Frederick Cottrell (#2555)

Cottrell@rlf.com

Jeffrey L. Moyer (#3309)

Moyer@rlf.com

Anne Shea Gaza (#4093)

Gaza@rlf.com

Richards, Layton & Finger P A.

One Rodney Square

920 North King Street

Wilmington, DE 19801

(302) 651-7700

Attorneys for Plaintiffs

Bayer HealthCare AG, Alcon, Inc., and

Alcon Manufacturing, Ltd.

OF COUNSEL:

Bruce R. Genderson

Adam L. Perlman

David I. Berl

Dov P. Grossman

Stanley E. Fisher

Williams & Connolly LLP

725 Twelfth Street, N.W.

Washington, DC 20005

(202) 434-5000

/s/ Richard D. Kirk

Richard D. Kirk (#922)

rkirk@bayardfirm.com

Ashley B. Stitzer (#3891)

astitzer@bayardfirm.com

The Bayard Firm

222 Delaware Ave., Suite 900

P.O. Box 25130

Wilmington, DE 19899

(302) 429-4242

Attorneys for Defendant

Teva Pharmaceuticals USA, Inc.

OF COUNSEL:

Bruce M. Gagala

M. Daniel Hefner

Brian A. Garcia

Leydig, Voit & Mayer, Ltd.

Two Prudential Plaza

180 N. Stetson Avenue




Suite 4900

Chicago, IL 60601

(312) 616-5600

Dated: May 1, 2007

Terms or Phrases	Plaintiffs' Proposed Construction	Defendant's Proposed Construction
The compounds defined by the preambles and the formulas presented in claims 1 and 2 (claims 8, 9 and 11 directly or indirectly referring to claim 1).	<p>'517 patent (claims 1, 2, 8, 9, and 11)</p> <p>Any compound of the structural formulas defined by the preambles and the structural formulas presented in claims 1 and 2.</p> <p>For clarity, plaintiffs contend that the claims encompass any compound possessing the connectivity of atoms set forth in the claims, including all stereoisomers, individually or any combination thereof, and not limited to racemates.</p>	The compounds defined by the preamble and the formula presented in claims 1, 2, 8, 9 and 11 are for a diastereomeric mixture in which there are two or more diastereomers, and a racemate of a single diastereomer. For clarity, Teva contends that the compounds defined by the preamble and the formula presented in the claims do not encompass a single enantiomer, or a mixture of a single enantiomer and its mirror image compound, other than as a racemate.
"[said compound] substantially free [of other enantiomers and stereoisomers]" (found in claim 1; claims 3 and 5 referring to claim 1).	<p>'942 patent (claims 1, 3, and 5)</p> <p>The phrase "substantially free" should be construed as "largely but not necessarily free."</p>	The phrase, to the extent it can be understood, means that any impurities consisting of "other enantiomers" or "other stereoisomers" must be below the detection limit for such enantiomers or stereoisomers.

'942 patent (claims 2, 4, and 7)		
<p>"The compound (1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolonecarboxylic acid) of the formula</p>  <p>"</p> <p>(found in claim 2; claims 4 and 7 referring to claim 2).</p>	<p>Any compound of the structural formula</p>  <p>For clarity, plaintiffs contend that the claims encompass any compound possessing the connectivity of atoms set forth in the claim, including all stereoisomers, individually or any combination thereof, and not limited to racemates.</p>	<p>The compounds defined by the preamble and the formula presented in claims 2, 4, and 7 are for a diastereomeric mixture in which there are two or more diastereomers, and a racemate of a single diastereomer. For clarity, Teva contends that the compounds defined by the preamble and the formula presented in the claims do not encompass a single enantiomer, or a mixture of a single enantiomer and its mirror image compound, other than as a racemate.</p>
<p>"moxifloxacin"</p>	<p>The compound</p> 	<p>The structure set forth at Col. 3, II. 38-48 of the '830 patent namely:</p> 